Xenetic Biosciences Q1 2026 net loss down 49% to $0.5M; royalty revenue up 36% to $0.8M

Xenetic Biosciences, Inc.

2026-Q1 EPS reported -$0.20 revenue$806,923

Net loss of $0.5M ($0.04 per share) vs $0.9M a year ago; cash $7.3M at March 31, 2026.
Royalty revenue $0.8M (+36% YoY) primarily from Takeda sublicense agreement.
R&D expenses $0.7M (-25% YoY) due to lower preclinical costs; G&A $0.6M, flat.
DNase I platform progress: translational data, manufacturing readiness, Israeli Ministry of Health approval for CAR T study.
Company continuing evaluation of strategic alternatives to maximize shareholder value.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Xenetic Biosciences, Inc. reported the three months ended March 31, 2026 results: revenue approximately $0.8 million, net income approximately $0.5 million.

Period: the three months ended March 31, 2026
Revenue: approximately $0.8 million
Net income: approximately $0.5 million
Result: reported results

Exact text from the filing

Royalty revenue for the three months ended March 31, 2026 increased approximately 36% to approximately $0.8 million, compared to approximately $0.6 million for the comparable prior year period, primarily driven by increased royalty payments recognized under the Company’s sublicense agreement with Takeda Pharmaceuticals Co. Ltd.

View on SEC.gov

572 earnings releases filed in the last 30 days. Browse all earnings releases →

Xenetic Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-26-003766

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.